Case reportSuccessful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab☆
Under a Creative Commons license
open access
Abbreviations
HBV
hepatitis B virus
HBsAg
hepatitis B surface antigen
Keywords
Entecavir
HBV reactivation
Rituximab
Cited by (0)
- ☆
The underlying research reported in this study was partially founded by the NIH (Grant No.: 5 T 32 DK007356-30 to M.J.S.). M.B. is a speaker and on the Advisory Board for Novartis, Gilead and Bristol Myers Squibb. R.E. is a speaker and on the Advisory Board for Gilead, Bristol Myers Squibb, Schering-Plough and Novartis. The other authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.
Copyright © 2009 European Association for the Study of the Liver. Published by Elsevier Ireland Ltd.